Two Sigma Securities’s Astria Therapeutics ATXS Stock Holding History

Two Sigma Securities’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,774	Closed	-$141K	–	1652
2025 Q4	$141K	Buy	+10,774	New	+$129K	0.02%	924
2021 Q1	–	Sell	-4,013	Closed	-$52K	–	868
2020 Q4	$52K	Buy	+4,013	New	+$71.5K	﹤0.01%	1556

Two Sigma Securities's ATXS Position: Q1 2026 in Review

Two Sigma Securities sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 10,774 shares — an estimated $141K sold.

Two Sigma Securities first reported a position in ATXS in Q4 2020 and held it in 2 quarters. The position peaked at $141K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Two Sigma Securities reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 10,774 Astria Therapeutics shares in Q1 2026, an estimated $141K.
Two Sigma Securities first reported a position in Astria Therapeutics in Q4 2020 and held it in 2 quarters.
Two Sigma Securities's Astria Therapeutics position peaked at $141K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.